Published by the C
International I
Myel T
oma Founda
ItionNSpG
ecial Edition: S
ASH 2006
VELCADE® (bortezomib) Issue
Welcome to the International Myeloma Foundation's (IMF) special edition of
CITINGS, our premiere publication featuring the most up-to-date information on myeloma
treatment. This issue focuses on VELCADE (bortezomib), the first of a new class of drugs called
proteasome inhibitors. In this issue, we provide a list of selected bortezomib data being presented
at the annual American Society of Hematology (ASH) Meeting to be held December 8­12, 2006.
As always, readers will also find a comprehensive list of references to the latest published studies
on bortezomib from both national and international medical journals and publications.
We hope that CITINGS provides a detailed and informative update of the VELCADE
literature, as well as assists in navigating the ASH meeting. Please feel free to contact the IMF at
(800) 452-CURE or www.myeloma.org
-- Susie Novis, President, IMF
American Society of Hematology Presentations 2006
Sunday, December 10, 2006
The Novel HDAC Inhibitor UCL67022 Is Highly Potent in Multiple Myeloma and Non-Hodgkins
Lymphoma and Is Enhanced by Bortezomib.
Lenushka Maharaj, Rakesh Popat, Angela Chahwan, Andrew T. Lister, James D. Cavenagh, Brian Middleton,
Alf Rioja, Charles Marson, Simon P. Joel
Time: 9:00 AM
Location: Hall E-1, Board #782-II
Abstract No: 2604
Session Type: Poster Session
Session Info: Poster Session: Molecular Pharmacology, Drug Resistance II (9:00 AM ­ 8:00 PM)
VELCADE/Dexamethasone (Vel/Dex) Versus VAD as Induction Treatment Prior to Autologous Stem
Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM): An Interim Analysis of
the IFM 2005-01 Randomized Multicenter Phase III Trial.
Jean-Luc Harousseau, Gerald Marit, Denis Caillot, Philippe Casassus, Thierry Facon, Mohamad Mohty,
Frederic Maloisel, Herve Maisonneuve, Carine Chaleteix, Lofti Benboubker, Dixie-Lee Esseltine, Michel Attal
Time: 4:45 PM
Location: Room 414 AB
Abstract No: 56
Session Type: Oral Session
Simultaneous Session: Clinical Results: Autologous Transplantation ­ Multiple Myeloma
(4:30 PM ­ 6:00 PM)
www.myeloma.org
(800) 452 - CURE (2873)
Funded by an educational grant from Millennium Pharmaceuticals, Inc.

---

Efficacy and Safety of Bortezomib in Systemic AL Amyloidosis ­ A Preliminary Report.
Ashutosh Wechalekar, Julian Gillmore, Helen Lachmann, Mark Offer, Philip Hawkins
Time: 5:00 PM
Location: Chapin Theater, Level III
Abstract No: 129
Session Type: Oral Session
Session Info: Simultaneous Session: Plasma Cell Dyscrasias, excluding Myeloma and Predictors
of Treatment Outcome (4:30 PM ­ 6:00 PM)
Bortezomib Induces Proliferation of Mesenchymal Progenitor Cells and Promotes Differentiation
towards Osteoblastic Lineage.
Siddhartha Mukherjee, Noopur Raje, Chirayu Patel, Sonia Vallet, Joshua Aronson, Shweta Chhetri,
Constantine Mitsiades, Teru Hideshima, Kenneth C. Anderson, David T. Scadden
Time: 5:15 PM
Location: Room 314
Abstract No: 88
Session Type: Oral Session
Simultaneous Session: Hematopoietic Stem Cell Niche (4:30 PM ­ 6:00 PM)
Survival of Genetic Subtypes of Relapsed Myeloma May Be Modulated by Secondary Events.
Wee-Joo Chng, George Mulligan, Barbara Bryant, Peter Leif Bergsagel
Time: 5:45 PM
Location: Chapin Theater, Level III
Abstract No: 132
Session Type: Oral Session
Simultaneous Session: Plasma Cell Dyscrasias, excluding Myeloma and Predictors of Treatment
Outcome (4:30 PM ­ 6:00 PM)
Monday, December 11, 2006
2-Methoxyestradiol in Combination with Velcade Results in an Augmentation of NFB Inhibition,
In Vitro Antiproliferative Activity and In Vivo Antitumor Efficacy in the RPMI-8226 Myeloma Model.
Patricia Burke, Glenn M. Swartz, Cassandra L. Waters, Xiaoru Chen, Theresa M. LaVallee,
Anthony M. Treston, William E. Fogler, Carolyn F. Sidor (Intr. by Carolyn Fowler Sidor)
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #750-III
Abstract No: 3521
Session Type: Poster Session
Poster Session: Myeloma: Biology and Pathophysiology, excluding Therapy V ­ Therapeutic
Implications (10:30 AM ­ 7:00 PM)
Alternating Bortezomib and Dexamethasone as Induction Regimen Prior to Autologous
Stem-Cell Transplantation in Newly Diagnosed Younger Patients with Multiple Myeloma:
Results of a PETHEMA Phase II Trial.
Laura Rosinol, Albert Oriol, M.-Victoria Mateos, Anna Sureda, Joaquin Diaz-Mediavilla, Adrian Alegre,
Juan-Jose Lahuerta, Javier De La Rubia, Carlos Herrero, Helgi Van de Velde, J.F. San Miguel, Joan Blade
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #315-III
Abstract No: 3086
Session Type: Poster Session
Poster Session: Clinical Results: Autologous Transplantation ­ Plasma Cell Dyscrasias
(10:30 AM ­ 7:00 PM)
www.myeloma.org
(800) 452 - CURE (2873)

---

Amplification of 1q21 Is Associated with Poor Outcome after Treatment with Bortezomib
in Relapsed/Refractory Multiple Myeloma.
Johannes Drach, Verena Sagaster, Victoria Odelga, Hannes Kaufmann, Jutta Ackermann, Markus Galhuber,
Niklas Zojer, Elisabeth Küenburg, Christoph Zielinski, Rotraud Wieser, Heinz Ludwig
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #627-III
Abstract No: 3398
Session Type: Poster Session
Poster Session: Myeloma: Biology and Pathophysiology, excluding Therapy I ­ Gene Expression
(10:30 AM ­ 7:00 PM)
Analysis of Varicella Zoster Virus Reactivation among Bortezomib-Treated Patients in the APEX Study.
Asher Alban Chanan-Khan, Pieter Sonneveld, Michael W. Schuster, David Irwin, Edward A. Stadtmauer,
Thierry Facon, Jean-Luc Harousseau, Dina Ben-Yehuda, Sagar Lonial, Hartmut Goldschmidt,
Donna E. Reece, Rachel B. Neuwirth, Kenneth C. Anderson, Paul G. Richardson
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #764-III
Abstract No: 3535
Session Type: Poster Session
Poster Session: Myeloma: Bortezomib-Based Therapies (10:30 AM ­ 7:00 PM)
Bortezomib Added to the Standard Mobilization Regimen of G-CSF and High-Dose
Cyclophosphamide Is a Safe and Effective Combination for a High Yield Stem Cell Collection While
Promoting Further Tumor Mass Reduction in Myeloma.
Jessica L. Stern, Brian Di Carlo, Michael W. Schuster, Tsiporah B. Shore, John G. Harpel, Roger Pearse,
Faiza Zafar, Joanne Dymek, Jessy Ryan, David Jayabalan, Selina Chen-Kiang, Scott Ely, John P. Leonard,
Morton Coleman, Ruben Niesvizky
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #182-III
Abstract No: 2953
Session Type: Poster Session
Poster Session: Clinical Care: Novel Regimens and Engraftment (10:30 AM ­ 7:00 PM)
Bortezomib and Thalidomide Treatment of Newly Diagnosed Patients with Multiple Myeloma ­
Efficacy and Neurotoxicity.
Ivan Borrello, Anna Ferguson, Carol Ann Huff, Shirley George, Barbara Biedryzcki, David Cornblath,
Vinay Chaudhry
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #757-III
Abstract No: 3528
Session Type: Poster Session
Poster Session: Myeloma: Bortezomib-Based Therapies (10:30 AM ­ 7:00 PM)
Bortezomib Down-Regulates HLA Class I and Enhances Natural Killer Cell Mediated Lysis of
Myeloma.
Jumei Shi, Tarun K. Garg, Rachel E. Kellum, Susann M. Szmania, Bart Barlogie, Guido Tricot,
Frits van Rhee
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #727-III
Abstract No: 3498
Session Type: Poster Session
Poster Session: Myeloma: Biology and Pathophysiology, excluding Therapy V ­ Therapeutic
Implications (10:30 AM ­ 7:00 PM)
www.myeloma.org
(800) 452 - CURE (2873)

---

Bortezomib in Combination with High-Dose Dexamethasone (HD dex) and Erythropoietin (EPO)
Does Not Result in an Increased Risk of Thromboembolic Complications.
Jean-Luc Harousseau, Sundar Jagannath, Paul G. Richardson, Pieter Sonneveld, Michael W. Schuster,
Dixie-Lee Esseltine, Kenneth C. Anderson
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #772-III
Abstract No: 3543
Session Type: Poster Session
Session Info: Poster Session: Myeloma: Bortezomib-Based Therapies (10:30 AM ­ 7:00 PM)
Breaking the Plateau Response in Myeloma: Preliminary Results of a Phase II Pilot Study of Sequential
Bortezomib in Combination with Dexamethasone and Pegylated Liposomal Doxorubicin (DoVeD) in
Patients No Longer Responsive to Standard Induction Regimens.
Brian A. Di Carlo, Jessica L. Stern, Michael Schuster, Tsiporah Shore, John Harpel, Roger Pearse, Faiza Zafar,
Joanne Dymek, Jessy Ryan, David Jayabalan, Selina Chen-Kiang, Scott Ely, John P. Leonard, Morton Coleman,
Ruben Niesvizky
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #767-III
Abstract No: 3538
Session Type: Poster Session
Poster Session: Myeloma: Bortezomib-Based Therapies (10:30 AM ­ 7:00 PM)
The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT)
Is an Effective Regimen for Relapsed/Refractory Myeloma and Reduces Serum Levels of Dickkopf-1,
RANKL, MIP-1 and Angiogenic Cytokines.
Evangelos Terpos, Athanasios Anagnostopoulos, Deborah Heath, Efstathios Kastritis, Dimitrios Christoulas,
Nikolaos Anagnostopoulos, Maria Roussou, Konstantinos Tsionos, Peter Croucher, Meletios A. Dimopoulos
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #770-III
Abstract No: 3541
Session Type: Poster Session
Poster Session: Myeloma: Bortezomib-Based Therapies (10:30 AM ­ 7:00 PM)
The Combination of Cyclophosphamide, Velcade and Dexamethasone (CVD) Induces High Response
Rates with Minimal Toxicity Compared to Velcade Alone (V) and Velcade Plus Dexamethasone (VD).
Faith E. Davies, Ping Wu, M. Srikanth, Matthew W. Jenner, Sharon Dines, Radovan Saso, Gareth J. Morgan
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #766-III
Abstract No: 3537
Session Type: Poster Session
Poster Session: Myeloma: Bortezomib-Based Therapies (10:30 AM ­ 7:00 PM)
The Combination of the mTOR Inhibitor Rapamycin and Proteasome Inhibitor Bortezomib Is
Synergistic In Vitro in Multiple Myeloma.
Garrett O'Sullivan, Xavier Leleu, Xiaoying Jia, Evdoxia Hatjiharisi, Hai Ngo, Anne-Sophie Moreau,
Yu-Tsu Tai, Douglas McMillin, Constantine Mitsiades, Noopur Raje, Teru Hideshima, Robert Schlossman,
Paul Richardson, Nikhil Munshi, Kenneth Anderson, Irene Ghobrial
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #724-III
Abstract No: 3495
Session Type: Poster Session
Poster Session: Myeloma: Biology and Pathophysiology, excluding Therapy V ­ Therapeutic
Implications (10:30 AM ­ 7:00 PM)
www.myeloma.org
(800) 452 - CURE (2873)

---

Cyclin D1 Overexpression Increases Chemosensitivity Via the Induction of Bim in Myeloma Cells.
Yoshiaki Kuroda, Akira Sakai, Naohiro Tsuyama, Shoso Munemasa, Nanae Nakaju, Mami Mizuno,
Yoshiko Okikawa, Yuta Katayama, Akiro Kimura
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #647-III
Abstract No: 3418
Session Type: Poster Session
Poster Session: Myeloma: Biology and Pathophysiology, excluding Therapy II ­ Gene Regulation
(10:30 AM ­ 7:00 PM)
Direct Assessment of Proteasomal Degradation as a Potential Predictor of Responsiveness to
Bortezomib in Multiple Myeloma
Giada Bianchi, Andrea Orsi, Simone Cenci, Paolo Cascio, Dharminder Chauhan, Kenneth C. Anderson,
Roberto Sitia
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #754-III
Abstract No: 3525
Session Type: Poster Session
Poster Session: Myeloma: Biology and Pathophysiology, excluding Therapy V ­ Therapeutic
Implications (10:30 AM ­ 7:00 PM)
Distinct Dynamic Profiles for NPI-0052-And Bortezomib-Induced Apoptosis in Multiple Myeloma.
Dharminder Chauhan, Ajita Singh, Mugdha Velankar, Teru Hideshima, Huib Ovaa, Celia Berkers, Giada
Bianchi, Roberto Sitia, Nikhil C. Munshi, Paul Richardson, Michael A. Palladino, Kenneth C. Anderson
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #625-III
Abstract No: 3396
Session Type: Poster Session
Poster Session: Myeloma: Biology and Pathophysiology, excluding Therapy I ­ Gene Expression
(10:30 AM ­ 7:00 PM)
Dysfunction of Toll-Like Receptor-2, -4, and -6: Is There a Role in the Pathogenesis of
Immunodeficiency in Multiple Myeloma?
Evangelos Terpos, Meletios A. Dimopoulos, Charoula Xirakia, Dimitrios Christoulas,
Athanasios Anagnostopoulos, Eirini Katodritou, Kostas Zervas, Paschalis Sideras, Konstantinos Tsionos,
Evangelos Andreakos
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #659-III
Abstract No: 3430
Session Type: Poster Session
Poster Session: Myeloma: Biology and Pathophysiology, excluding Therapy III ­ Signaling Pathways
(10:30 AM ­ 7:00 PM)
Effects of a Novel Histone Deacetylase Inhibitor, PXD101, When Used as Monotherapy or in
Combination with Bortezomib on Tumor Growth in Mouse Models of Human Multiple Myeloma.
Richard A. Campbell, Eric Sanchez, Haiming Chen, Lauren Turker, Olivia Trac, Mingjie Li, Dror Shalitin,
Melinda S. Gordon, Shen Pang, Benjamin Bonavida, Jonathan Said, Michael Jeffers, Xiaozhong Qian,
Henri S. Lichenstein, James R. Berenson
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #712-III
Abstract No: 3483
Session Type: Poster Session
Poster Session: Myeloma: Biology and Pathophysiology, excluding Therapy IV ­ Novel Agents
(10:30 AM ­ 7:00 PM)
www.myeloma.org
(800) 452 - CURE (2873)

---

Enhancing Activity of Bortezomib Against Multiple Myeloma (MM) through Inhibition of Interleukin
(IL)-6 Signaling: A Role for Repression of Myeloid Cell Leukemia (Mcl)-1.
Peter M. Voorhees, George W. Small, Deborah J. Kuhn, Qing Chen, Sally A. Hunsucker, Robert Corringham,
Carlos A. Garay, Mohamed H. Zaki, Jeffrey Nemeth, Robert Z. Orlowski
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #643-III
Abstract No: 3414
Session Type: Poster Session
Poster Session: Myeloma: Biology and Pathophysiology, excluding Therapy II ­ Gene Regulation
(10:30 AM ­ 7:00 PM)
Escalation Treatment Algorithm with Bortezomib, Dexamethasone and Bendamustine for Patients
with Relapsed or Refractory Multiple Myeloma: A Single Centre Experience.
Roland Fenk, Mark Michael, Fabian Zohren, Thorsten Graef, Arkosch Czibere, Sebastian Balleisen,
Frank Neumann, Ulrich-Peter Rohr, Ulrich Steidl, Rainer Haas, Guido Kobbe
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #769-III
Abstract No: 3540
Session Type: Poster Session
Poster Session: Myeloma: Bortezomib-Based Therapies (10:30 AM ­ 7:00 PM)
Final Results of a Phase II Study of Bortezomib (Velcade) in Combination with Liposomal Doxorubicin
(Doxil) and Thalidomide (VDT) Demonstrate a Sustained High Response Rates in Patients (pts) with
Relapsed (rel) or Refactory (ref) Multiple Myeloma.
Asher Alban Chanan-khan, Swaminathan Padmanabhan, Kena C. Miller, Laurie Musiel, Jihnhee Yu,
Zale P. Bernstein, Rami Manochakian, Myron S. Czuczman
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #768-III
Abstract No: 3539
Session Type: Poster Session
Poster Session: Myeloma: Bortezomib-Based Therapies (10:30 AM ­ 7:00 PM)
A Gene Expression Based Centrosome Index Is a Powerful Prognostic Factor in Myeloma.
Wee-Joo Chng, Rafael Fonseca
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #617-III
Abstract No: 3388
Session Type: Poster Session
Poster Session: Myeloma: Biology and Pathophysiology, excluding Therapy I ­ Gene Expression
(10:30 AM ­ 7:00 PM)
Hematopoietic Stroma Confers Resistance to Immune Control by TRAIL in Multiple Myeloma
through Induction of FLIP.
Lia Perez, Nancy Parquet, Ken Shain, Ramadevi Nimmanapalli, Melissa Alsina, Claudio Anasetti,
William S. Dalton
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #653-III
Abstract No: 3424
Session Type: Poster Session
Poster Session: Myeloma: Biology and Pathophysiology, excluding Therapy III ­ Signaling Pathways
(10:30 AM ­ 7:00 PM)
www.myeloma.org
(800) 452 - CURE (2873)

---

High Rate of Complete and near Complete Responses (CR/nCR) after Initial Therapy with
Bortezomib (Velcade), Doxil, and Dexamethasone (VDD) Is Further Increased after Autologous Stem
Cell Transplantation (ASCT).
Andrzej J. Jakubowiak, Ammar Al-Zoubi, Tara Kendall, Judah Friedman, Asra Ahmed, Yasser Khaled,
Shin Mineishi, Mark S. Kaminski
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #322-III
Abstract No: 3093
Session Type: Poster Session
Poster Session: Clinical Results: Autologous Transplantation ­ Plasma Cell Dyscrasias (10:30 AM­7:00 PM)
Impact of Early Consolidation with Bortezomib, Thalidomide and Dexamethasone on Molecularly-
Detectable Disease in MM Patients in CR or VGPR Following Autologous Transplantation:
Uncommon Achievement of Molecular Remission Despite Evidence of Tumor Load Reduction
by Real Time PCR.
Marco Ladetto, Monica Astolfi, Loredana Santo, Ilaria Avonto, Federica Cavallo, Gloria Pagliano,
Patrizia Pregno, Mariella Grasso, Anna Marina Liberati, Tommaso Caravita, Francesco Pisani,
Tommasina Guglielmelli, Elisa Genuardi, Rossana Crivelli, Carmen Cristiano, Daniela Drandi,
Mario Boccadoro, Antonio Palumbo
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #329-III
Abstract No: 3100
Session Type: Poster Session
Poster Session: Clinical Results: Autologous Transplantation ­ Plasma Cell Dyscrasias (10:30 AM­7:00 PM)
Inhibition of Kinesin Spindle Protein Induces Apoptosis and Overcomes Drug Resistance in Models of
Multiple Myeloma.
Qing Chen, Vishwan Pamarthi, Deborah J. Kuhn, Peter M. Voorhees, John S. Strader, Robert Z. Orlowski
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #654-III
Abstract No: 3425
Session Type: Poster Session
Poster Session: Myeloma: Biology and Pathophysiology, excluding Therapy III ­ Signaling Pathways
(10:30 AM ­ 7:00 PM)
Lenalidomide and Bortezomib Inhibit Osteoclast Differentiation and Activation in Multiple Myeloma:
Clinical Implications.
Iris Breitkreutz, Sonia Vallet, Marc S. Raab, Yu-Tzu Tai, Noopur Raje, Teru Hideshima,
Dharminder Chauhan, Nikhil C. Munshi, Paul Richardson, Kenneth C. Anderson
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #714-III
Abstract No: 3485
Session Type: Poster Session
Poster Session: Myeloma: Biology and Pathophysiology, excluding Therapy V ­ Therapeutic
Implications (10:30 AM ­ 7:00 PM)
Neurotoxicity of Bortezomib Therapy in Multiple Myeloma (MM): A Single Center Experience.
Ashraf Badros, Jay S. Dalal, Olga Goloubeva, Jenni Thompson, Kelly Yager, Can Ilyas, Aaron P. Rapoport,
Robert G. Fenton, Gorgun Akpek, Saul Yanovich, Edward Sausville
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #763-III
Abstract No: 3534
Session Type: Poster Session
Poster Session: Myeloma: Bortezomib-Based Therapies (10:30 AM ­ 7:00 PM)
www.myeloma.org
(800) 452 - CURE (2873)

---

The Novel, Irreversible Proteasome Inhibitor PR-171 Demonstrates Potent Anti-Tumor Activity in
Pre-Clinical Models of Multiple Myeloma, and Overcomes Bortezomib Resistance.
Deborah J. Kuhn, Qing Chen, Peter M. Voorhees, John S. Strader, Kevin D. Shenk, Congcong M. Sun,
Susan D. Demo, Mark K. Bennett, Fred W. van Leeuwen, Robert Z. Orlowski
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #690-III
Abstract No: 3461
Session Type: Poster Session
Poster Session: Myeloma: Biology and Pathophysiology, excluding Therapy IV ­ Novel Agents
(10:30 AM ­ 7:00 PM)
An Observational, Retrospective Analysis of Retreatment with Bortezomib of Mulitple Myeloma (MM)
Patients.
Therese M. Conner, QuynhChau D. Doan, Annette L. LeBlanc, Ian B. Walters, Roy A. Beveridge
(Intr. by Jing L Marantz)
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #760-III
Abstract No: 3531
Session Type: Poster Session
Poster Session: Myeloma: Bortezomib-Based Therapies (10:30 AM ­ 7:00 PM)
The Pan-Bcl-2 Inhibitor GX15-O70 Induces Apoptosis in Human Myeloma Cells by Noxa Induction
and Strongly Enhances Melphalan, Bortezomib or TRAIL-R1 Antibody Apoptotic Effect.
Patricia Gomez-Bougie, Sophie Maïga, Catherine Pellat-Deceunynck, Sandrine Jouan, Regis Bataille,
Martine Amiot (Intr. by Jean-Luc Harousseau)
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #705-III
Abstract No: 3476
Session Type: Poster Session
Poster Session: Myeloma: Biology and Pathophysiology, excluding Therapy IV ­ Novel Agents
(10:30 AM ­ 7:00 PM)
Phase I Study of Bortezomib and 153Sm-Lexidronam Combination for Refractory and Relapsed
Multiple Myeloma.
James R. Berenson, Regina A. Swift, Russell Mapes, Christina D. Abaya
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #773-III
Abstract No: 3544
Session Type: Poster Session
Poster Session: Myeloma: Bortezomib-Based Therapies (10:30 AM ­ 7:00 PM)
A Phase I/II Trial of Bortezomib, Low Dose Intravenous Melphalan and Dexamethasone for Patients
with Relapsed Multiple Myeloma.
Rakesh Popat, Catherine Williams, Mark Cook, Charles Craddock, Supratik Basu, Charles Singer, Liz Odeh,
Nicola Foot, Heather Oakervee, James D. Cavenagh
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #771-III
Abstract No: 3542
Session Type: Poster Session
Poster Session: Myeloma: Bortezomib-Based Therapies (10:30 AM ­ 7:00 PM)
www.myeloma.org
(800) 452 - CURE (2873)

---

A Phase I-II Trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone for Relapsed/Refractory
Multiple Myeloma
Donna E. Reece, Giovanni Piza, Suzanne Trudel, Mariela Pantoja, Christine Chen, Joseph R. Mikhael,
Vishal Kukreti, Keith Stewart
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #765-III
Abstract No: 3536
Session Type: Poster Session
Poster Session: Myeloma: Bortezomib-Based Therapies (10:30 AM ­ 7:00 PM)
Phase II Trial of Bortezomib Combined with Weekly Doxorubicin and Oral Dexamethasone for
Relapsed or Refractory Multiple Myeloma (MM): Effect of NF-B Activation on Response.
Natalie S. Callander, Shigeki Miyamoto, Brad Kahl, Stephanie Markovina, Martha Raschko, Jae Werndl,
Catherine Leith, Alice McCoy
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #774-III
Abstract No: 3545
Session Type: Poster Session
Poster Session: Myeloma: Bortezomib-Based Therapies (10:30 AM ­ 7:00 PM)
Phase II Trial of SCIO-469 as Monotherapy (M) or in Combination with Bortezomib (MB) in
Relapsed Refractory Multiple Myeloma (MM).
David S. Siegel, A. Krishnan, S. Lonial, G. Chatta, M. Alsina, S. Jagannath, P. Richardson, R.J. Hohl,
J.A. Lust, W. Bensinger, G. Carrum, J. Moreb, A. Simic, B. Barlogie, R.T. Maziarz, K.C. Anderson, J. Lin,
A. Lowe, S. Vetticaden, J. Zhu
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #809-III
Abstract No: 3580
Session Type: Poster Session
Poster Session: Myeloma: Novel Agents and Toxicities (10:30 AM ­ 7:00 PM)
Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Two Doses of Bortezomib (Btz) in
Patients with Relapsed Multiple Myeloma (MM).
A. Keith Stewart, Dan Sullivan, Sagar Lonial, Ann F. Mohrbacher, Gurkamal Chatta, Chaim Shustik,
Howard Burris III, Michael Karol, Peter Zannikos, Donna E. Reece
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #762-III
Abstract No: 3533
Session Type: Poster Session
Poster Session: Myeloma: Bortezomib-Based Therapies (10:30 AM ­ 7:00 PM)
Preliminary Safety and Efficacy Results from an International Phase 3b Study for Expanded Access to
Bortezomib in 624 Patients with Relapsed and/or Refractory Multiple Myeloma.
Joseph R. Mikhael, Andrew Belch, Miles Prince, Maria Nambo Lucio, Angelo Maiolino, Alessandro Corso,
Maria Teresa Petrucci, Komarnicki Mieczyslaw, A. Keith Stewart
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #759-III
Abstract No: 3530
Session Type: Poster Session
Poster Session: Myeloma: Bortezomib-Based Therapies (10:30 AM ­ 7:00 PM)
www.myeloma.org
(800) 452 - CURE (2873)

---

Relationship between Quality of Response to Bortezomib (btz) and Clinical Benefit in Multiple
Myeloma (MM) in the APEX and SUMMIT Studies.
Ruben Niesvizky, P.G. Richardson, P. Sonneveld, M.W. Schuster, M. Coleman, D. Irwin, E.A. Stadtmauer,
T. Facon, J. Harousseau, A. Boral, K.C. Anderson
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #758-III
Abstract No: 3529
Session Type: Poster Session
Poster Session: Myeloma: Bortezomib-Based Therapies (10:30 AM ­ 7:00 PM)
Retrospective Analysis of Fractionated High-Dose Melphalan (F-MEL) and Bortezomib-Thalidomide-
Dexamethasone (VTD) with Autotransplant (AT) Support for Advanced and Refractory Multiple
Myeloma (AR-MM).
Mauricio Pineda-Roman, Michelle H. Fox, Klaus A. Hollmig, Elias J. Anaissie, Frits van Rhee, Guido Tricot,
Maurizio Zangari, Abid Mohiuddin, Bart Barlogie
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #331-III
Abstract No: 3102
Session Type: Poster Session
Poster Session: Clinical Results: Autologous Transplantation ­ Plasma Cell Dyscrasias (10:30 AM­7:00 PM)
Single Agent Bortezomib Is Associated with a High Response Rate in Patients with High Risk
Myeloma. A Phase II Study from the Eastern Cooperative Oncology Group (E2A02).
Angela Dispenzieri, Lijung Zhang, Rafael Fonseca, David H. Vesole, Philip R. Greipp
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #756-III
Abstract No: 3527
Session Type: Poster Session
Poster Session: Myeloma: Bortezomib-Based Therapies (10:30 AM ­ 7:00 PM)
Targeting PKC in Multiple Myeloma: In Vitro and In Vivo Effects of the Novel, Orally Available
Small-Molecule Inhibitor Enzastaurin (LY317615.HCl).
Marc S. Raab, Klaus Podar, Jing Zhang, Douglas McMillin, Iris Breitkreutz, Yu-Tzu Tai, Boris Lin,
Irene Ghobrial, Nikhil Munshi, Teru Hideshima, Dharminder Chauhan, Kenneth C. Anderson
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #695-III
Abstract No: 3466
Session Type: Poster Session
Poster Session: Myeloma: Biology and Pathophysiology, excluding Therapy IV ­ Novel Agents
(10:30 AM ­ 7:00 PM)
Utility of Bortezomib Retreatment for Patients with Relapsed Multiple Myeloma.
Jeffrey Lee Wolf, Paul Richardson, Michael Schuster, Annette LeBlanc, David Battleman, Ian Walters
Time: 10:30 AM ­ 7:00 PM
Location: Hall E-1, Board #761-III
Abstract No: 3532
Session Type: Poster Session
Poster Session: Myeloma: Bortezomib-Based Therapies (10:30 AM ­ 7:00 PM)
www.myeloma.org
(800) 452 - CURE (2873)

---

The Combination of Pegylated Liposomal Doxorubicin and Bortezomib Significantly Improves Time
to Progression of Patients with Relapsed/Refractory Multiple Myeloma Compared with Bortezomib
Alone: Results from a Planned Interim Analysis of a Randomized Phase III Study.
Robert Z. Orlowski, Sen H. Zhuang, Trilok Parekh, Liang Xiu, Jean-Luc Harousseau, the DOXIL-MMY-3001
Study Investigators
Time: 11:15 AM
Location: Chapin Theater, Level III
Abstract No: 404
Session Type: Oral Session
Simultaneous Session: Treatment of Relapsed/Refractory Myeloma (11:00 AM ­ 12:30 PM)
Lenalidomide Plus Bortezomib (Rev-Vel) in Relapsed and/or Refractory Multiple Myeloma (MM):
Final Results of a Multicenter Phase 1 Trial.
Paul G. Richardson, S. Jagannath, D.E. Avigan, M. Alsina, R.L. Schlossman, A. Mazumder, N.C. Munshi,
I. Ghobrial, D. Doss, M.L. McKenney, M.G. Farrell, D.L. Warren, L.E. Lunde, B. Gourley, S. Vaccaro,
C. Delaney, S. Pountney, C.S. Mitsiades, T. Hideshima, C. Byrne, R. Knight, A. Birner, T. Myers, E. Weller,
K.C. Anderson
Time: 11:30 AM
Location: Chapin Theater, Level III
Abstract No: 405
Session Type: Oral Session
Simultaneous Session: Treatment of Relapsed/Refractory Myeloma (11:00 AM ­ 12:30 PM)
A Multicenter Phase 1 Clinical Trial of Tanespimycin (KOS-953) + Bortezomib (BZ): Encouraging
Activity and Manageable Toxicity in Heavily Pre-Treated Patients with Relapsed Refractory Multiple
Myeloma (MM).
Paul Richardson, Asher Alban Chanan-Khan, Sagar Lonial, Amrita Krishnan, Melissa Alsina,
Michael Carroll, Karen Adler, G. Cropp, C. Mitsiades, Robert Johnson, Alison Hannah, Kenneth C. Anderson
Time: 11:54 AM
Location: Chapin Theater, Level III
Abstract No: 406
Session Type: Oral Session
Simultaneous Session: Treatment of Relapsed/Refractory Myeloma (11:00 AM ­ 12:30 PM)
Combination of Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) for Relapsed Multiple
Myeloma: Results of a Phase I/II Clinical Trial.
Antonio Palumbo, Maria Teresa Ambrosini, Giulia Benevolo, Patrizia Pregno, Norbert Pescosta,
Vincenzo Callea, Clotilde Cangialosi, Tommaso Caravita, Fortunato Morabito, Pellegrino Musto,
Sara Bringhen, Francesca Gay, Cecilia Rus, Mario Boccadoro
Time: 12:00 PM
Location: Chapin Theater, Level III
Abstract No: 407
Session Type: Oral Session
Simultaneous Session: Treatment of Relapsed/Refractory Myeloma (11:00 AM ­ 12:30 PM)
Bortezomib Reduces Serum Dickkopf-1 and RANKL Concentrations and Normalizes Indices of Bone
Remodeling in Patients with Relapsed Multiple Myeloma.
Evangelos Terpos, Deborah Heath, Amin Rahemtulla, Kostas Zervas, Andrew Chantry, Athanasios
Anagnostopoulos, Anastasia Pouli, Eirini Katodritou, Evgenia Verrou, Elisavet C. Vervessou,
Meletios A. Dimopoulos, Peter Croucher
Time: 1:45 PM
Location: Chapin Theater, Level III
Abstract No: 506
Session Type: Oral Session
Simultaneous Session: Multiple Myeloma: Bone Biology (1:30 PM ­ 3:00 PM)
www.myeloma.org
(800) 452 - CURE (2873)

---

Combination of the Proteasome Inhibitor Bortezomib and a Histone Deacetylase Inhibitor PXD101
Results in Synergistic Inhibition of Osteoclastogenesis and Significantly Stronger Inhibition of
Multiple Myeloma Growth In Vitro and In Vivo.
Rentian Feng, Ana B. Oton, Kenneth Patrene, Gulsum Anderson, Markus Y. Mapara, Chandra Belani,
David Roodman, Suzanne Lentzsch
Time: 2:00 PM
Location: Chapin Theater, Level III
Abstract No: 507
Session Type: Oral Session
Simultaneous Session: Multiple Myeloma: Bone Biology (1:30 PM ­ 3:00 PM)
The Proteasome Inhibitor Bortezomib Affects Osteoblastogenesis and Bone Formation In Vitro and In
Vivo in Multiple Myeloma Patients.
Nicola Giuliani, Francesca Morandi, Sara Tagliaferri, Mirca Lazzaretti, Sabrina Bonomini,
Monica Crugnola, Daniela Petrò, Cristina Mancini, Eugenia Martella, Vittorio Rizzoli
Time: 2:15 PM
Location: Chapin Theater, Level III
Abstract No: 508
Session Type: Oral Session
Simultaneous Session: Multiple Myeloma: Bone Biology (1:30 PM ­ 3:00 PM)
PTH and Bortezomib Suppress Growth of Primary Human Myeloma through Increased Bone
Formation In Vivo.
Angela Pennisi, Wen Ling, Paul Perkins, Rinku Saha, Xin Li, Bart Barlogie, Guido Tricot, Maurizio Zangari,
Shmuel Yaccoby
Time: 2:30 PM
Location: Chapin Theater, Level III
Abstract No: 509
Session Type: Oral Session
Simultaneous Session: Multiple Myeloma: Bone Biology (1:30 PM ­ 3:00 PM)
Tuesday, December 12, 2006
Long-Term Follow-Up of Patients Treated with Bortezomib Alone and in Combination with
Dexamethasone as Frontline Therapy for Multiple Myeloma.
Sundar Jagannath, Brian G.M. Durie, Jeffrey Lee Wolf, Elber S. Camacho, David Irwin, Jose Lutzky,
Marti McKinley, Afshin Eli Gabayan, Amitabha Mazumder, John Crowley, Robert Vescio
Time: 8:45 AM
Location: Halls F1-F2
Abstract No: 796
Session Type: Oral Session
Simultaneous Session: Induction Therapy for Newly Diagnosed Myeloma (8:00 AM ­ 10:00 AM)
Bortezomib and Pegylated Liposomal Doxorubicin as Induction Therapy for Adult Patients with
Symptomatic Multiple Myeloma: Cancer and Leukemia Group B Study 10301.
Robert Z. Orlowski, Bercedis L. Peterson, Ben Sanford, Asher A. Chanan-Khan, Lee M. Zehngebot,
Peter R. Watson, Michael A. Caligiuri, Richard A. Larson, the Cancer and Leukemia Group B
Time: 9:00 AM
Location: Halls F1-F2
Abstract No: 797
Session Type: Oral Session
Simultaneous Session: Induction Therapy for Newly Diagnosed Myeloma (8:00 AM ­ 10:00 AM)
www.myeloma.org
(800) 452 - CURE (2873)

---

A Humanized Anti-IGF-1R Monoclonal Antibody (AVE1642) Synergizes with Bortezomib To Induce
Apoptosis in CD45neg Myeloma Cells.
Geraldine Descamps, Soraya Wuilleme-Toumi, Patricia Gomez-Bougie, Corinne Venot, Friedhelm Bladt,
Regis Bataille, Martine Amiot (Intr. by Jean-Luc Harousseau)
Time: 9:00 AM
Location: Room 110
Abstract No: 845
Session Type: Oral Session
Simultaneous Session: Multiple Myeloma: Novel Targeted Therapy (8:00 AM ­ 10:00 AM)
Bortezomib Enhances Melphalan Response by Altering Fanconi Anemia (FA)/BRCA Pathway
Expression and Function.
Danielle N. Yarde, Lori A. Hazlehurst, Vasco A. Oliveira, Qing Chen, William S. Dalton
Time: 9:45 AM
Location: Room 315
Abstract No: 840
Session Type: Oral Session
Simultaneous Session: Mechanisms of Resistance: Determinants of Response (8:00 AM ­ 10:00 AM)
Hsp90 Inhibitors Deliver a Death Signal Via the Endoplasmic Reticulum Stress Pathway in Myeloma.
Emma L. Davenport, Hannah Moore, Alan Dunlop, Paul Workman, Gareth J. Morgan, Faith E. Davies
Time: 9:45 AM
Location: Room 110
Abstract No: 848
Session Type: Oral Session
Simultaneous Session: Multiple Myeloma: Novel Targeted Therapy (8:00 AM ­ 10:00 AM)
Publication Only
Antiproliferative and Proapoptotic Effect of Vitamin D in Bortezomib (B) Resistant Human Myeloma
Cell Line (HMCL).
Asher Alban Chanan-Khan, Michelle Romano, Paula Pera, Noreen Ersing, Josephia Muindi,
Donald L. Trump, Candace Johnson
Abstract No: 5074
Session Type: Publication Only
Antitumour Activity of Bortezomib-Pegylated Liposomal Doxorubicine Association: Results of an
Ongoing Study in Multiple Myeloma Patients.
Giulia Braccalenti, Pasqualinda Ferrara, Marta Gubbiotti, Paola Cerroni, Rita Emili, Maria Grazia
Morandi, Roberta Pace, Anna Marina Liberati
Abstract No: 5116
Session Type: Publication Only
www.myeloma.org
(800) 452 - CURE (2873)

---

Bortezomib, Adriamycin Dexamethasone (PAD) Combination Therapies or Patients with Relapsed or
Refractory Myeloma Previously Treated with VAD or VAD like Therapy.
Treen C. Morris, Mary Drake, Paul J. Kettle, Aishleen Brunton, James D. Cavenagh, Heather E. Oakervee,
Michael O'Dwyer, Margaret Murray, Tanya O'Shea, Gordon Cook
Abstract No: 5117
Session Type: Publication Only
Bortezomib Once Weekly Is Well Tolerated as Maintenance Therapy after Less Than a Complete
Response to High-Dose Melphalan in Patients with Multiple Myeloma.
Stefan Knop, Holger Hebart, Volker Kunzmann, Ralf Angermund, Hermann Einsele (Intr. by Ralf Bargou)
Abstract No: 5099
Session Type: Publication Only
Bortezomib Therapy Response Is Independent of Cytogenetic Abnormalities in Relapsed/Refractory
Multiple Myeloma.
Young Hong Chang
Abstract No: 5081
Session Type: Publication Only
Changes in Serum Free Light Chain and Biochemical Markers in Patients with Multiple Myeloma
Receiving Bortezomib Treatment.
Chang-Ki Min, Ki-Seong Eom, Seok Lee, Jong-Wook Lee, Woo-Sung Min, Chong-Won Park, Chun-Choo Kim,
Myungshin Kim, Jihyang Lim, Yonggoo Kim, Kyungja Han
Abstract No: 5028
Session Type: Publication Only
Characterization of Bortezomib Resistant Human Multiple Myeloma Cell Line (HMCL): A Clinically
Relevant Model for Novel Drug Development in Multiple Myeloma (MM).
Asher Alban Chanan-Khan, Noreen Ersing, Paula Pera, Ralph Bernaki, Lionel Coignet, David W. Goodrich,
Raya Haung, Carl W. Porter
Abstract No: 5050
Session Type: Publication Only
Combination Chemotherapy Including Velcade in Patients with Refractory or Relapsed Multiple
Myeloma.
YuHong Zhou, QingHong Yu, ZhiPing Hu, BaoDong Ye, YiPing Shen, JianPing Shen, LongXi Yu (Intr. by
He Huang)
Abstract No: 5090
Session Type: Publication Only
Combination High-Dose Cyclophosphamide and Bortezomib Is Safe and Effective for Stem Cell
Harvesting in Chemotherapy Refractory Multiple Myeloma.
Miriam Katzman, Theresa George, Heather Doell, Patricia Danyluk, Sheri Briggs, Wanda Hasegawa,
Christian Fibich, Michael Voralia
Abstract No: 5459
Session Type: Publication Only
www.myeloma.org
(800) 452 - CURE (2873)

---

Effect of Bortezomib on the Autonomic Nervous System.
Roberto Crocchiolo, Stefania Ferrari, Valeria Calbi, Magda Marcatti, Elena Guggiari, Paolo Servida,
Massimo Bernardi, Ubaldo Del Carro, Chiara Bonini, Moreno Tresoldi, Jacopo Peccatori, Fabio Ciceri,
Maria Grazia Natali Sora (Intr. by Chiara Bonini)
Abstract No: 5101
Session Type: Publication Only
Factors Influencing Responsiveness to Bortezomib in Patients with Multiple Myeloma Suggest a
Possible Role for Host Immunocompetency.
Gerrard Teoh, Daryl Tan, William Hwang, Liang Piu Koh, Charles Chuah, Heng Joo Ng
Abstract No: 5100
Session Type: Publication Only
Fever Following Bortezomib Administration Correlated with Serum Cytokine Levels in Patients with
Multiple Myeloma (MM).
Dai Maruyama, Takashi Watanabe, Fusako Ohara, Kazuki Tanimoto, Sung-Won Kim, Satoshi Yamasaki,
Yuriko Morita, Yukio Kobayashi, Kensei Tobinai
Abstract No: 5092
Session Type: Publication Only
Final Results of a Prospective, Non-Interventional Study on Bortezomib (Velcade®, VEL) in the
Treatment of Multiple Myeloma (MM) in Office-Based Hematology Units (OBH).
Wolfgang Ulrich Knauf, Burkhard Otremba, Friedrich Overkamp, Susanne Bammer, Ralf Angermund
Abstract No: 5109
Session Type: Publication Only
Liposomal Doxorubicin (Myocet®) Enhance the Efficacy of Bortezomib, Dexamethasone Plus
Thalidomide in Refractory Myeloma.
Stefania Ciolli, Franco Leoni, Cinzia Casini, Carla Breschi, Alberto Bosi
Abstract No: 5087
Session Type: Publication Only
PAD Is a Highly Effective Regimen for the Treatment of Patients with Relapsed Refractory Multiple
Myeloma.
Michel Delforge, Ann Janssens, Daan Dierickx, Johan Maertens, Koen Theunissen, Peter Vandenberghe,
Gregor Verhoef
Abstract No: 5095
Session Type: Publication Only
Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of Bortezomib (B) in Patients (pts) with
Relapsed Multiple Myeloma (MM): A Phase I/II Study in Japan.
Kensei Tobinai, Takashi Watanabe, Yoshiaki Ogawa, Michinori Ogura, Yasuo Morishima, Hironobu Minami,
Kuniaki Itoh, Tomomitsu Hotta
Abstract No: 5106
Session Type: Publication Only
Phase I/II Trial of Bortezomib Maintenance Following Autolgous Peripheral Blood Progenitor Cell
Transplantation as Treatment for Intermediate- and Advanced-Stage Multiple Myeloma.
Gary J. Schiller, J. Phillip Sohn, R. Malone, K. Bartone, B. Habtemariam, R. Paquette, Sven De Vos, M. Territo
Abstract No: 5433
Session Type: Publication Only
www.myeloma.org
(800) 452 - CURE (2873)

---

Quantitative Detection Using SYBR Green of Residual Disease in Myeloma Patients Treated with
Revlimid or Velcade.
Kyle J. Thulien, Tony Reiman, Andrew R. Belch, Johnathan Booth, Linda M. Pilarski
Abstract No: 5102
Session Type: Publication Only
Response to Bortezomib in Combination after Relapse o Non-Response to First Treatment with
Bortezomib Alone in Myeloma Multiple Patients.
Araceli Rubio-Martinez, Valle Recasens, Pilar Delgado, Juan Carlos Garcia-Zueco, Daniel Rubio-Felix,
Pilar Giraldo
Abstract No: 5094
Session Type: Publication Only
Safety and Efficacy of Bortezomib (VELCADETM) in 104 Patients with Relapsed and/or Refractory Multiple
Myeloma Who Have Received at Least Two Previous Lines of Therapy: Impact of Cytogenetics on Response from
a Canadian Cohort. Joseph R. Mikhael, Donna E. Reece, Andrew Belch, Nizar J. Bahlis, Deepa Sharma
Abstract No: 5118
Session Type: Publication Only
Ten-Year Overall Survival Analysis of Current Treatments of Relapsed or Refractory Multiple Myeloma
in Canada.
Donna Reece, Daniel Grima, Cheryl Attard, Kim Yoong, Farah Jivraj
Abstract No: 5517
Session Type: Publication Only
Uptake of New Therapeutics in the Treatment of Multiple Myeloma (MM) in Germany (GER)
­ Results from a Representative Multicentre Treatment Survey 2006.
Ralf Angermund, W. Knauf, M. Freund, M. Nowrousian, H. Einsele, H. Goldschmidt, W. Berdel, W. Poenisch,
C. Straka, L. Kellermann, H. Pliskat
Abstract No: 5110
Session Type: Publication Only
Use of Immunoglobulin Infusions in the Management of Bortezomib-Induced Peripheral Neuropathy
in Multiple Myeloma.
Gerrard Teoh, Daryl Tan, William Hwang, Liang Piu Koh, Charles Chuah, Heng Joo Ng
Abstract No: 5097
Session Type: Publication Only
Velcade as Retreatment of Multiple Myeloma Patients Previously Responsive to Velcade.
Maria Teresa Petrucci, Cristiano Gallucci, Vincenzo Federico, Patrizia Del Bianco, Robert Foa
Abstract No: 5088
Session Type: Publication Only
www.myeloma.org
(800) 452 - CURE (2873)

---

2nd Quarter 2006 VELCADE® (Bortezomib) Publications
Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in
vitro sensitivity and tumor necrosis factor alpha response with clinical activity.
Strauss SJ, Maharaj L, Hoare S, Johnson PW, Radford JA, Vinnecombe S, Millard L, Rohatiner A, Boral A,
Trehu E, Schenkein D, Balkwill F, Joel SP, Lister TA.
J Clin Oncol. 2006 May 1;24(13):2105-12.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16606971&query_hl=1&itool=pubmed_DocSum
This study concludes that bortezomib demonstrates encouraging efficacy in mantle cell lymphoma in
heavily pretreated individuals.
Clinical implications of chromosomal abnormalities in multiple myeloma.
Terpos E, Eleutherakis-Papaiakovou V, Dimopoulos MA.
Leuk Lymphoma. 2006 May;47(5):803-14.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16753864&query_hl=1&itool=pubmed_DocSum
The authors define and discuss high-risk prognostic groups that are not generally controlled with high-
dose melphalan and autologous stem cell transplantation, and should therefore be treated with newer
therapeutic agents.
Enhancing care and managing side effects in patients receiving bortezomib.
Colson K.
Clin Adv Hematol Oncol. 2006 May;4(5):6-7; discussion 8; suppl 13.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16832860&query_hl=1&itool=pubmed_DocSum
No abstract available.
Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell
support in patients with refractory or relapsed myeloma.
Palumbo A, Avonto I, Bruno B, Falcone A, Scalzulli PR, Ambrosini MT, Bringhen S, Gay F, Rus C, Cavallo F,
Falco P, Massaia M, Musto P, Boccadoro M.
Clin Lymphoma Myeloma. 2006 May;6(6):475-7.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16796778&query_hl=1&itool=pubmed_DocSum
This study concludes that melphalan/bortezomib/thalidomide/dexamethasone showed encouraging
antimyeloma activity in patients with advanced-stage myeloma.
www.myeloma.org
(800) 452 - CURE (2873)

---

A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for
multiple myeloma.
Bang SM, Lee JH, Yoon SS, Park S, Min CK, Kim CC, Suh C, Sohn SK, Min YH, Lee JJ, Kim K, Seong CM,
Yoon HJ, Cho KS, Jo DY, Lee KH, Lee NR, Kim CS; Korean Multiple Myeloma Working Party.
Int J Hematol. 2006 May;83(4):309-13.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16757429&query_hl=1&itool=pubmed_DocSum
Bortezomib has demonstrated clinical activity in patients with multiple myeloma (MM), but no prior
toxicity data are available for Asian patients who have used bortezomib for MM. In this study, as com-
pared to Western studies, the incidences of thrombocytopenia and neurotoxicity were similar; however,
gastrointestinal toxicities were relatively low in comparison. Significant neuropathy was associated with
the number of prior regimens and combination with thalidomide.
Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
Richardson P.
Clin Adv Hematol Oncol. 2006 May;4(5):4-5; discussion 8; suppl 13.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16832859&query_hl=1&itool=pubmed_DocSum
No abstract available.
Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.
Richardson P, Jagannath S, Colson K.
Clin Adv Hematol Oncol. 2006 May;4(5):1; discussion 8; suppl 13.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16830422&query_hl=1&itool=pubmed_DocSum
This review discusses what is known thus far about the efficacy and safety profile of bortezomib,
ways for optimizing treatment with bortezomib, and strategies for managing side effects and enhancing
quality of life.
The proteasome: a novel target for anticancer therapy.
Montagut C, Rovira A, Albanell J.
Clin Transl Oncol. 2006 May;8(5):313-7.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16760005&query_hl=1&itool=pubmed_DocSum
The authors discuss bortezomib as an extremely potent and selective proteasome inhibitor that shows
strong activity related to in vitro and in vivo laboratory studies against many solid and hematologic
tumor types.
www.myeloma.org
(800) 452 - CURE (2873)

---

The safety and efficacy of bortezomib in relapsed multiple myeloma.
Jagannath S.
Clin Adv Hematol Oncol. 2006 May;4(5):2-3; discussion 8; suppl 13.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16830423&query_hl=1&itool=pubmed_DocSum
No abstract available.
Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of
Th1 cytokines.
Blanco B, Perez-Simon JA, Sanchez-Abarca LI, Carvajal-Vergara X, Mateos J, Vidriales B, Lopez-Holgado N,
Maiso P, Alberca M, Villaron E, Schenkein D, Pandiella A, San Miguel J.
Blood. 2006 May 1;107(9):3575-83. [Epub 2005 Nov 10.]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16282346&query_hl=1&itool=pubmed_DocSum
This study concludes that at concentrations reached in the clinical setting, bortezomib induces selective
apoptosis and decreases Th1 response among alloreactive T lymphocytes while it barely affects un-stimu-
lated T cells. These results establish the basis for the clinical use of bortezomib in the management of
graft-versus-host disease.
Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP
skeletally targeted radiotherapy in an orthotopic model of multiple myeloma.
Goel A, Dispenzieri A, Geyer SM, Greiner S, Peng KW, Russell SJ.
Blood. 2006 May 15;107(10):4063-70. [Epub 2006 Jan 19.]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16424391&query_hl=1&itool=pubmed_DocSum
The authors conclude that bortezomib is a potent, selective in vivo radiosensitizer that may substantially
affect the efficacy of skeletal-targeted radiotherapy in multiple myeloma.
United States Food and Drug Administration approval summary: bortezomib for the treatment of
progressive multiple myeloma after one prior therapy.
Kane RC, Farrell AT, Sridhara R, Pazdur R.
Clin Cancer Res. 2006 May 15;12(10):2955-60.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16707588&query_hl=1&itool=pubmed_DocSum
The U.S. FDA had earlier (May 2003) granted bortezomib accelerated approval for the treatment of
patients with MM progressing after two prior therapies. The results of the phase 3 trial and the FDA
analysis of the data, along with the sponsor's completion of other postmarketing commitments, confirm
bortezomib's benefit and support regular approval.
www.myeloma.org
(800) 452 - CURE (2873)

---

Apoptosis: a relevant tool for anticancer therapy.
Russo A, Terrasi M, Agnese V, Santini D, Bazan V.
Ann Oncol. 2006 Jun;17 Suppl 7:vii115-vii123.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16760273&query_hl=1&itool=pubmed_DocSum
This review provides an update of certain molecular players that are already in use in order to target
apoptosis (such as bortezomib) or which are still being clinically evaluated (such ONYX-015, survivin
and exisulind/aptosyn) or which, following preclinical studies, might have the necessary requirements
for becoming part of the anticancer drug programs (such as TRAIL/Apo2L, apoptin/VP3).
Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance
or maintain remission status.
Kroger N, Zabelina T, Ayuk F, Atanackovic D, Schieder H, Renges H, Zander A.
Exp Hematol. 2006 Jun;34(6):770-5.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16728282&query_hl=1&itool=pubmed_DocSum
This study concludes that bortezomib after allgoeneic stem cell transplantation (SCT) is effective, but
further studies are needed to balance the efficacy with potential hazards such as infectious complica-
tions, aggravation of graft-versus-host disease, and neurotoxicity.
Bortezomib: new indication. Second-line treatment of myeloma: limited efficacy, major risks.
No authors listed.
Prescrire Int. 2006 Jun;15(83):98-100.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16764098&query_hl=1&itool=pubmed_DocSum
This article concludes that bortezomib is an alternative to steroid therapy for patients with multiple
myeloma in whom first-line treatment has failed and who do not qualify for stem cell grafting. The
choice of treatment must be discussed with the patient, after providing thorough information on the
likely benefits and risks.
Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic
hematopoietic cell transplantation.
Bruno B, Patriarca F, Sorasio R, Mattei D, Montefusco V, Peccatori J, Bonifazi F, Petrucci MT, Milone G,
Guidi S, Giaccone L, Rotta M, Fanin R, Boccadoro M, Corradini P.
Haematologica. 2006 Jun;91(6):837-9.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16769588&query_hl=1&itool=pubmed_DocSum
The authors retrospectively evaluated the efficacy of bortezomib in 23 patients with muliple myeloma
who had relapsed after allografting. After a median follow-up of 6 months, progression free survival was
6 months. Twenty-one patients are alive, two and five in continuous very good partial and complete
remissions, respectively.
www.myeloma.org
(800) 452 - CURE (2873)

---

Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and
impaired renal function.
Nozza A, Siracusano L, Armando S.
Clin Ther. 2006 Jun;28(6):953-9.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16860177&query_hl=1&itool=pubmed_DocSum
The authors report a case of an elderly patient 78 year-old white male with refractory myeloma and
progression with renal failure who responded to bortezomib treatment. Bortezomib was well tolerated in
this patient.
An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in
patients treated with the novel proteasome inhibitor bortezomib.
Stubblefield MD, Slovin S, MacGregor-Cortelli B, Muzzy J, Scher H, Wright J, Esseltine D, Schenkein D,
O'Connor OA.
Clin Oncol (R Coll Radiol). 2006 Jun;18(5):410-8.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16817333&query_hl=1&itool=pubmed_DocSum
This study concludes that bortezomib can cause a predominately sensory axonal polyneuropathy. Pre-
existing peripheral nervous system disorders, such as neuropathy and radiculopathy, are common in
patients with cancer, and may pre-dispose to the development of symptomatic neuronal toxicity when
treated with bortezomib. Baseline electrodiagnostic evaluation may identify patients with pre-existing
peripheral nervous system disorders at risk for additive neuronal toxicity from neurotoxic chemothera-
peutic agents.
Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by
modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.
Navas TA, Nguyen AN, Hideshima T, Reddy M, Ma JY, Haghnazari E, Henson M, Stebbins EG, Kerr I,
O'Young G, Kapoun AM, Chakravarty S, Mavunkel B, Perumattam J, Luedtke G, Dugar S, Medicherla S,
Protter AA, Schreiner GF, Anderson KC, Higgins LS.
Leukemia. 2006 Jun;20(6):1017-27.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16617327&query_hl=1&itool=pubmed_DocSum
The authors conclude that in addition to its role in suppressing an activated multiple myeloma micro-
environment, co-treatment with a p38 inhibitor, such as SCIO-469, may enhance the cytotoxicity of
bortezomib by modulating pro-apoptotic and anti-apoptotic factors in myeloma cells, suggesting great
potential for co-therapy.
www.myeloma.org
(800) 452 - CURE (2873)

---

LAGlambda-1: a clinically relevant drug resistant human multiple myeloma tumor murine model
that enables rapid evaluation of treatments for multiple myeloma.
Campbell RA, Manyak SJ, Yang HH, Sjak-Shie NN, Chen H, Gui D, Popoviciu L, Wang C, Gordon M,
Pang S, Bonavida B, Said J, Berenson JR.
Int J Oncol. 2006 Jun;28(6):1409-17.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16685443&query_hl=1&itool=pubmed_DocSum
The authors generate new human myeloma tumors that grow in immunodeficient mice and can be used
for pathophysiological studies and rapid evaluation of new therapies.
Aggresome induction by proteasome inhibitor bortezomib and {alpha}-tubulin hyperacetylation by
tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.
Catley L, Weisberg E, Kiziltepe T, Tai YT, Hideshima T, Neri P, Tassone P, Atadja P, Chauhan D, Munshi NC,
Anderson KC.
Blood. 2006 Jun 13; [Epub ahead of print.]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16728695&query_hl=1&itool=pubmed_DocSum
The data presented by the authors confirms the potential clinical benefit of combing histone deacetylase
inhibitors with proteasome inhibitors, and provides insight into the mechanisms of synergistic anti-
myeloma activity of bortezomib in combination with LBH589.
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma:
results of a multicenter phase I/II study.
Mateos MV, Hernandez JM, Hernandez MT, Gutierrez NC, Palomera L, Fuertes M, Diaz-Mediavilla J,
Lahuerta JJ, de la Rubia J, Terol MJ, Sureda A, Bargay J, Ribas P, de Arriba F, Alegre A, Oriol A, Carrera D,
Garcia-Larana J, Garcia-Sanz R, Blade J, Prosper F, Mateo G, Esseltine DL, van de Velde H, San Miguel JF.
Blood. 2006 Jun 13; [Epub ahead of print.]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16772605&query_hl=1&itool=pubmed_DocSum
The authors conclude that for elderly myeloma patients ineligible for transplant, the combination of
bortezomib with melphalan plus prednisone (MP) appears significantly superior to MP alone. In their
study, the combination produced very high complete response (CR) rates, including immunophenotypic
CR, even in patients with poor prognostic features.
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells.
Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP, Boise LH.
Blood. 2006 Jun 15;107(12):4907-16. [Epub 2006 Feb 28.]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16507771&query_hl=1&itool=pubmed_DocSum
The authors demonstrate that 5 different multiple myeloma cell lines display similar patterns of sensi-
tivity to 3 proteasome inhibitors (PIs) but respond differently to specific NF-kappaB inhibition. They
further show that PIs initiate the unfolded protein response, a signaling pathway activated by the accu-
mulation of misfolded proteins within the endoplasmic reticulum.
www.myeloma.org
(800) 452 - CURE (2873)

---

Extramedullary disease and targeted therapies for hematological malignancies ­ is the association real?
Raanani P, Shpilberg O, Ben-Bassat I.
Ann Oncol. 2006 Jun 21; [Epub ahead of print.]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16790518&query_hl=1&itool=pubmed_DocSum
Extramedullary involvement is a rare manifestation of acute and chronic leukemia and of multiple
myeloma (MM). Nevertheless, with the expanding use of targeted treatments there is an impression that
the incidence of extramedullary relapses is increasing. The authors review the reports on this phenom-
enon, including in patients treated with thalidomide and bortezomib for MM.
Additional dexamethasone improves the response rate among patients with multiple myeloma treated
with single agent bortezomib.
Cavenagh JD.
Haematologica. 2006 Jul;91(7):869B.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16818270&query_hl=1&itool=pubmed_DocSum
Comment on: Haematologica. 2006 Jul;91(7):929-34.
Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG)
in multiple myeloma.
Duus J, Bahar HI, Venkataraman G, Ozpuyan F, Izban KF, Al-Masri H, Maududi T, Toor A, Alkan S.
Leuk Lymphoma. 2006 Jul;47(7):1369-78.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16923571&query_hl=1&itool=pubmed_DocSum
This study suggests that targeted inhibition of heat shock protein 90 may prove to be a valid and inno-
vative strategy for the development of future therapeutic options for myeloma patients.
Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies.
Caravita T, de Fabritiis P, Palumbo A, Amadori S, Boccadoro M.
Nat Clin Pract Oncol. 2006 Jul;3(7):374-87.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16826218&query_hl=1&itool=pubmed_DocSum
The authors summarize the principal clinical trials of bortezomib and discuss its efficacy in solid and
hematologic tumors.
Bortezomib for multiple myeloma.
Popat R, Joel S, Oakervee H, Cavenagh J.
Expert Opin Pharmacother. 2006 Jul;7(10):1337-46.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16805719&query_hl=1&itool=pubmed_DocSum
This review describes the pharmacology, toxicity, preclinical and clinical activity of bortezomib, predom-
inantly in the setting of multiple myeloma.
www.myeloma.org
(800) 452 - CURE (2873)

---

Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or
refractory multiple myeloma with less than optimal response to bortezomib alone.
Jagannath S, Richardson PG, Barlogie B, Berenson JR, Singhal S, Irwin D, Srkalovic G, Schenkein DP,
Esseltine DL, Anderson KC; SUMMIT/CREST Investigators.
Haematologica. 2006 Jul;91(7):929-34.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16818280&query_hl=1&itool=pubmed_DocSum
The authors conclude that the addition of dexamethasone to bortezomib in patients with relapsed
and/or refractory myeloma, who had suboptimal responses to bortezomib alone, was associated with
improvement in responses without prohibitive toxicity.
Dexamethasone reduces the risk of bortezomib-induced pulmonary complications in Japanese
myeloma patients.
Shimazaki C, Kobayashi Y, Inaba T, Taniwaki M.
Int J Hematol. 2006 Jul;84(1):90-1.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16867910&query_hl=1&itool=pubmed_DocSum
No abstract available.
Emerging role of novel combinations for induction therapy in multiple myeloma.
Voorhees PM, Orlowski RZ.
Clin Lymphoma Myeloma. 2006 Jul;7(1):33-41.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16879768&query_hl=1&itool=pubmed_DocSum
The authors review the early promising clinical activity of regimens that include novel therapeutic
agents for the treatment of patients with newly diagnosed myeloma.
Perspective on the current use of bortezomib in multiple myeloma.
San-Miguel J, Blade J.
Haematologica. 2006 Jul;91(7):871-2.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16818272&query_hl=1&itool=pubmed_DocSum
Comment on: Haematologica. 2006 Jul;91(7):1001 and Haematologica. 2006 Jul;91(7):929-34.
Proteasome inhibition in multiple myeloma.
Kropff M, Bisping G, Wenning D, Berdel WE, Kienast J.
Eur J Cancer. 2006 Jul;42(11):1623-39. [Epub 2006 Jul 3.]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16820291&query_hl=1&itool=pubmed_DocSum
The authors discuss the preclinical and clinical phase I studies, as well as the initial phase II studies,
combining bortezomib with conventional chemotherapy or thalidomide in support of the assumption
that bortezomib sensitizes myeloma cells to these drugs, resulting in additive or synergistic activity.
www.myeloma.org
(800) 452 - CURE (2873)

---

Proteasome Inhibitor Induces Apoptosis through Induction of Endoplasmic Reticulum Stress.
Fribley A, Wang CY.
Cancer Biol Ther. 2006 Jul;5(7):745-8. Epub 2006 Jul 1.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16861900&query_hl=1&itool=pubmed_DocSum
This review discusses recent progress on the elucidation of the molecular mechanism of PS-341 (also
known as Velcade or bortezomib)-mediated apoptosis.
The role of the bone microenvironment in the pathophysiology and therapeutic management of
multiple myeloma: Interplay of growth factors, their receptors and stromal interactions.
Mitsiades CS, Mitsiades NS, Munshi NC, Richardson PG, Anderson KC.
Eur J Cancer. 2006 Jul;42(11):1564-73. [Epub 2006 Jun 9.]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16765041&query_hl=1&itool=pubmed_DocSum
This review focuses on recent progress in the study of interactions of myeloma cells with their local
microenvironment and also addresses ongoing research into cell adhesion- and cytokine-mediated mech-
anisms, which has already provided several new molecular targets and corresponding therapeutic strate-
gies, such as the proteasome inhibitor bortezomib and thalidomide derivatives (e.g. lenalidomide), for
the management of myeloma.
State of the art therapy in multiple myeloma and future perspectives.
Denz U, Haas PS, Wasch R, Einsele H, Engelhardt M.
Eur J Cancer. 2006 Jul;42(11):1591-600. [Epub 2006 Jul.]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16815703&query_hl=1&itool=pubmed_DocSum
This review considers recent clinical advancements in anti-myeloma strategies and provides an overview
of the state of the art management of myeloma patients.
Synergistic antimyeloma effects of zoledronate and simvastatin.
Schmidmaier R, Simsek M, Baumann P, Emmerich B, Meinhardt G.
Anticancer Drugs. 2006 Jul;17(6):621-9.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16917207&query_hl=1&itool=pubmed_DocSum
This study provides a rationale for combining zoledronate and simvastatin with classical antimyeloma
drugs, such as melphalan and bortezomib.
An update: Health economics of managing multiple myeloma.
Moeremans K, Annemans L.
Eur J Cancer. 2006 Jul;42(11):1684-91. [Epub 2006 Jun 16.]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16781867&query_hl=1&itool=pubmed_DocSum
The authors conclude that there is a clear need for peer reviewed economic evaluations of novel therapies
such as thalidomide and bortezomib in the treatment of multiple myeloma at different stages of the disease.
www.myeloma.org
(800) 452 - CURE (2873)

---

Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced
multiple myeloma with bortezomib.
Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D,
Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K,
Esseltine D, Anderson KC, Amato AA.
J Clin Oncol. 2006 Jul 1;24(19):3113-20. [Epub 2006 Jun 5.]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16754936&query_hl=1&itool=pubmed_DocSum
The authors seek to determine the frequency, characteristics, and reversibility of peripheral neuropathy
from bortezomib treatment of advanced multiple myeloma. They conclude that bortezomib-associated
peripheral neuropathy seems reversible in the majority of patients after dose reduction and discontinua-
tion, and that although severe neuropathy was more frequent in the presence of baseline neuropathy, the
overall occurrence was independent of baseline neuropathy or type of prior therapy.
Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of
multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis.
Wu KD, Zhou L, Burtrum D, Ludwig DL, Moore MA.
Cancer Immunol Immunother. 2006 Jul 11; [Epub ahead of print.]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16832681&query_hl=1&itool=pubmed_DocSum
The authors test a fully human anti-IGF-IR antibody (A12) against mutiple myeloma (MM), and show
specific inhibition of IGF-I or serum -induced IGF-IR signaling in MM cells in vitro. The A12 is also
evaluated in combination with other drugs (bortezomib, melphalan). The authors find that the tumor
burden is sharply decreased, and overall survival is significantly prolonged, when the therapies are com-
bined.
Bortezomib in relapsed multiple myeloma complicated by extramedullary plasmacytomas.
Hughes M, Micallef-Eynaud P.
Clin Lab Haematol. 2006 Aug;28(4):267-9.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16898968&query_hl=1&itool=pubmed_DocSum
The authors address the case of a 58-year-old man suffering a relapse of multiple myeloma complicated
by large intra-abdominal extramedullary plasmacytomas and severe hepatic impairment secondary to bil-
iary obstruction. Combination therapy with bortezomib and dexamethasone resulted in partial response
of the plasmacytomas and complete resolution of his hepatic impairment.
Complete remission upon bortezomib-dexamethasone therapy in three heavily pretreated multiple
myeloma patients relapsing after allogeneic stem cell transplantation.
Tosi P, Zamagni E, Cangini D, Tacchetti P, Perrone G, Ceccolini M, Baccarani M, Cavo M.
Ann Hematol. 2006 Aug;85(8):549-51. [Epub 2006 Apr 13.]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16614846&query_hl=1&itool=pubmed_DocSum
No abstract available.
www.myeloma.org
(800) 452 - CURE (2873)

---

Proteasome inhibitor bortezomib as an anticancer drug [Article in Japanese].
Yasui H, Hideshima T.
Tanpakushitsu Kakusan Koso [Protein, Nucleic Acid, Enzyme]. 2006 Aug;51(10 Suppl):1251-6.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16922383&query_hl=1&itool=pubmed_DocSum
No abstract available.
Proteasome inhibitor bortezomib for the treatment of multiple myeloma.
Cavo M.
Leukemia. 2006 Aug;20(8):1341-52. [Epub 2006 Jun 29.]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16810203&query_hl=1&itool=pubmed_DocSum
The author discusses the history of bortezomib's clinical trials and suggests that bortezomib offers great
promise both to overcome the resistance to conventional chemotherapy and to serve as the backbone for
the development of more effective treatment strategies to improve patient outcome in myeloma.
Tumor lysis syndrome early after treatment with bortezomib for multiple myeloma.
Kenealy MK, Prince HM, Honemann D.
Pharmacotherapy. 2006 Aug;26(8):1205-6; discussion 1206.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16863501&query_hl=1&itool=pubmed_DocSum
No abstract available.
Severe pulmonary complication after bortezomib treatment for multiple myeloma.
Boyer JE, Batra RB, Ascensao JL, Schechter GP.
Blood. 2006 Aug 1;108(3):1113.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16861361&query_hl=1&itool=pubmed_DocSum
No abstract available.
Inefficacy of bortezomib therapy for CNS involvement of refractory multiple myeloma.
Mele G, Pinna S, Alloro E, Brocca MC, Coppi MR, Quarta G.
Leuk Res. 2006 Aug 3; [Epub ahead of print].
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16890285&query_hl=1&itool=pubmed_DocSum
The authors report the very rare case of a 57-year-old male patient affected by refractory stage IIIA
light-chain multiple myeloma (MM) who developed CNS invasion during bortezomib therapy.
www.myeloma.org
(800) 452 - CURE (2873)

---

Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment.
Heider U, Kaiser M, Muller C, Jakob C, Zavrski I, Schulz CO, Fleissner C, Hecht M, Sezer O.
Eur J Haematol. 2006 Sep;77(3):233-8.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16923110&query_hl=1&itool=pubmed_DocSum
This study shows that treatment with bortezomib leads to enhanced markers of osteoblast activity in
patients with myeloma. The comparison with the control group suggests that the effect on osteoblasts is
unique to the proteasome inhibitor.
Bortezomib dosing in relapsed multiple myeloma.
Jagannath S.
Clin Lymphoma Myeloma. 2006 Sep;7(2):101-2.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=17026818&query_hl=26&itool=pubmed_DocSum
No abstract available.
New drugs for myeloma [Article in French].
Moreau P.
Presse Med. 2006 Sep;35(9 Pt 2):1303-8.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16969325&query_hl=1&itool=pubmed_DocSum
The author discusses thalidomide, bortezomib, and lenalidomide treatment alone and in combination,
concluding that their effectiveness in combination will result in their eventual replacement of conven-
tional myeloma chemotherapies.
Response to bortezomib and activation of osteoblasts in multiple myeloma.
Zangari M, Yaccoby S, Cavallo F, Esseltine D, Tricot G.
Clin Lymphoma Myeloma. 2006 Sep;7(2):109-14.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=17026821&query_hl=26&itool=pubmed_DocSum
The authors discuss the observation that increased alkaline phosphatase (ALP) in patients responding
to bortezomib is associated with a parallel increase in bone-specific ALP and parathyroid hormone,
suggesting that response to bortezomib in multiple myeloma is closely associated with osteoblastic acti-
vation. Variation in markers of osteoblastic activation, such as ALP, have also predicted response and
response duration in patients treated with bortezomib.
Weekly bortezomib/methylprednisolone is effective and well tolerated in relapsed multiple myeloma.
Suvannasankha A, Smith GG, Juliar BE, Abonour R.
Clin Lymphoma Myeloma. 2006 Sep;7(2):131-4.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=17026824&query_hl=26&itool=pubmed_DocSum
This study explores weekly bortezomib/methylprednisolone in patients with relapsed multiple myeloma
and finds this regimen to be well-tolerated, yielding a response rate comparable with the standard sched-
ule of bortezomib alone.
www.myeloma.org
(800) 452 - CURE (2873)

---

Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory
multiple myeloma.
Chang H, Trieu Y, Qi X, Xu W, Stewart KA, Reece D.
Leuk Res. 2006 Sep 20; [Epub ahead of print.]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16996589&query_hl=29&itool=pubmed_DocSum
The authors find that bortezomib is an effective salvage therapy for refractory/relapsed myeloma, irre-
spective of genetic risk factors.
Recent advances in the treatment of Multiple Myeloma.
Yasui H, Hideshima T, Richardson PG, Anderson KC.
Curr Pharm Biotechnol. 2006 Oct;7(5):381-93.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=17076653&query_hl=3&itool=pubmed_DocSum
The authors discuss the mechanisms of action of novel drugs (including bortezomib/Velcade) and their
clinical applications, alone or combined with conventional or novel drugs.
Thalidomide in multiple myeloma: past, present and future.
Harousseau JL.
Future Oncol. 2006 Oct;2(5):577-89.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=17026450&query_hl=3&itool=pubmed_DocSum
The author discusses thalidomide as one of the most active agents in relapsed myeloma and, demon-
strated more recently, its use as part of frontline therapy.
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma:
results of a multicenter phase 1/2 study.
Mateos MV, Hernandez JM, Hernandez MT, Gutierrez NC, Palomera L, Fuertes M, Diaz-Mediavilla J,
Lahuerta JJ, de la Rubia J, Terol MJ, Sureda A, Bargay J, Ribas P, de Arriba F, Alegre A, Oriol A, Carrera D,
Garcia-Larana J, Garcia-Sanz R, Blade J, Prosper F, Mateo G, Esseltine DL, van de Velde H, Miguel JF.
Blood. 2006 Oct 1;108(7):2165-72. [Epub 2006 Jun 13.]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16772605&query_hl=29&itool=pubmed_DocSum
This study concludes that for elderly myeloma patients ineligible for transplantation, the combination
of bortezomib plus melphalan plus prednisone (MP) appears significantly superior to MP-alone, pro-
ducing very high complete response (CR) rates, including immunophenotypic CRs, even in patients
with poor prognostic features.
www.myeloma.org
(800) 452 - CURE (2873)

---

A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.
Chauhan D, Velankar M, Brahmandam M, Hideshima T, Podar K, Richardson P, Schlossman R, Ghobrial I,
Raje N, Munshi N, Anderson KC.
Oncogene. 2006 Oct 2; [Epub ahead of print.]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=17016430&query_hl=29&itool=pubmed_DocSum
The authors characterize the effects of ABT-737, a potent small-molecule protein inhibitor, and finds
that combining ABT-737 with bortezomib, melphalan, or dexamethasone induces additive anti-multiple
myeloma activity.
Can NF-kappaB be a target for novel and efficient anti-cancer agents?
Olivier S, Robe P, Bours V.
Biochem Pharmacol. 2006 Oct 30;72(9):1054-68. [Epub 2006 Sep 14.]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16973133&query_hl=26&itool=pubmed_DocSum
The most significant clinical data demonstrating that the NF-kappB transcription factor can, in most
cases, protect transformed cells from apoptosis have been obtained with bortezomib, a proteasome
inhibitor, for the treatment of multiple myeloma. This review discusses the preclinical and clinical data
obtained with various drugs and their putative future developments.
Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma.
Richardson PG, Mitsiades C, Ghobrial I, Anderson K.
Curr Opin Oncol. 2006 Nov;18(6):598-608.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=16988581&query_hl=29&itool=pubmed_DocSum
The authors discuss bortezomib-combination treatments and find that they show promising activity in
relapsed or refractory myeloma, including reversal of chemoresistance to previously used agents.
Bortezomib and dexamethasone treatment prior to autologous transplantation in newly diagnosed
multiple myeloma.
Dispenzieri A.
Haematologica. 2006 Nov;91(11):1444.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=17082002&query_hl=26&itool=pubmed_DocSum
No abstract available.
www.myeloma.org
(800) 452 - CURE (2873)

---

Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation
in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.
Harousseau JL, Attal M, Leleu X, Troncy J, Pegourie B, Stoppa AM, Hulin C, Benboubker L, Fuzibet JG,
Renaud M, Moreau P, Avet-Loiseau H.
Haematologica. 2006 Nov;91(11):1498-505. [Epub 2006 Oct 17.]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=17043025&query_hl=26&itool=pubmed_DocSum
The authors explore whether the use of novel agents may increase the complete remission rate of newly
diagnosed multiple myeloma patients before autologous stem cell transplantation, which may improve
post-transplantation response and survival. They find that their regimen of bortezomib plus dexamthea-
sone appears effective and well tolerated in newly diagnosed myeloma patients.
Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma.
Ramadan KM, McKenna KE, Morris TC.
Lancet Oncol. 2006 Nov;7(11):958-9.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=17081923&query_hl=26&itool=pubmed_DocSum
No abstract available.
Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib
in patients with multiple myeloma.
Wu KL, Heule F, Lam K, Sonneveld P.
J Am Acad Dermatol. 2006 Nov;55(5):897-900. [Epub 2006 Aug 22.]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list
_uids=17052502&query_hl=26&itool=pubmed_DocSum
The authors conduct observational analysis of 47 patients with myeloma who are treated with bortezo-
mib in 3 prospective clinical trials, and observe adverse reactions in 6 patients (13%).
www.myeloma.org
(800) 452 - CURE (2873)

---